ICON Public Limited Company (NASDAQ:ICLR) is among the cheap healthcare stocks to buy heading into 2026. On December 4, BMO Capital maintained its ‘Market Perform’ rating and $175 price target on ICON Public Limited Company (NASDAQ:ICLR) after the analyst call with management. During the call, many topics were discussed, including senior executive change and ongoing trends surrounding cancellations. The analyst also assessed the company’s dynamics in functional work relative to its full-service offerings, ...

投资策略表现 - Brown Capital Management International All-Company策略在2025年第二季度的表现优于MSCI ACWI美国除外指数（上涨12.30%）和MSCI EAFE指数（上涨12.07%）[1] - 第二季度初因4月2日解放日导致全球股市抛售，随后在90天关税缓期后市场出现反弹[1] - 在此环境下，国际股票表现尤为强劲，大幅飙升[1] ICON公司概况 - ICON Public Limited Company是一家总部位于爱尔兰都柏林的临床研究组织，为制药、生物技术和医疗器械公司提供外包开发和商业化服务[2][3] - 该公司是最大的临床试验及相关服务提供商之一，支持新药和新设备的开发[3] - 其服务包括管理I至IV期临床试验、生物分析和临床实验室服务、试验设计的数据分析和技术、监管咨询以及营销策略[3] ICON公司股价表现 - 截至2025年9月25日，ICON公司股价报收于每股162.53美元，市值为126.4亿美元[2] - 该股一个月回报率为-8.66%，过去52周内其股价价值损失了43.09%[2] - Brown Capital Management International All-Company策略持有ICON公司股份已超过十年[3]